Emergence of antibiotic-resistant pneumococcal serotypes causing invasive pneumococcal disease in children, Spain
Pneumococcal conjugate vaccines (PCVs) have significantly reduced disease burden caused by Streptococcus pneumoniae, a leading cause of childhood morbidity and mortality globally. The rise of non-vaccine serotypes is a frequent phenomenon after the use of these PCVs. This study is a national surveil...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/424088 |
| Acceso en línea: | http://hdl.handle.net/10261/424088 |
| Access Level: | acceso abierto |
| Palabra clave: | Invasive pneumococcal diseases Pneumococcal conjugated vaccine Resistant antibiotics Serotype replacement |
| Sumario: | Pneumococcal conjugate vaccines (PCVs) have significantly reduced disease burden caused by Streptococcus pneumoniae, a leading cause of childhood morbidity and mortality globally. The rise of non-vaccine serotypes is a frequent phenomenon after the use of these PCVs. This study is a national surveillance that includes all pneumococcal isolates causing invasive pneumococcal disease (IPD) (4,455 isolates) in the pediatric population to analyze the changes of strains with reduced susceptibility (IPD-RS) to different antibiotics (1,458 to penicillin/1,304 to erythromycin) and the impact of PCVs and COVID-19 pandemic on antibiotic resistance. Six periods are differentiated according to this decline: pre-PCV13, early PCV13, middle PCV13, late PCV13, COVID-19, and reopening. Between 2009 and 2023, overall IPD cases in Spain decreased by over 60% in children aged 1–4 years and by approximately 50% in infants under 1 year of age. Nevertheless, an increase in IPD-RS caused by non-PCV13 serotypes was observed, with serotype 24F being the most prevalent, which is not included in the currently licensed PCVs. The introduction of PCV13 showed a substantial impact on reducing IPD in children. The COVID-19 pandemic led to a temporary decline in the burden of disease caused by resistant strains in 2020 due to non-pharmacological measures followed by a subsequent recovery. |
|---|